

(19)



(11)

EP 3 634 998 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

Corrected version no 1 (W1 B1)**Corrections, see****Bibliography INID code(s) 73**

(48) Corrigendum issued on:

09.04.2025 Bulletin 2025/15

(45) Date of publication and mention of the grant of the patent:

26.02.2025 Bulletin 2025/09(21) Application number: **18729644.7**(22) Date of filing: **04.06.2018**

(51) International Patent Classification (IPC):

C07K 16/18 ^(2006.01) **C07K 16/24** ^(2006.01)**C07K 16/28** ^(2006.01) **C07K 16/32** ^(2006.01)

(52) Cooperative Patent Classification (CPC):

C07K 16/2809; C07K 16/2866; C07K 16/32;**C07K 2317/24; C07K 2317/31; C07K 2317/33;****C07K 2317/567; C07K 2317/622; C07K 2317/626;****C07K 2317/75; C07K 2317/92; C07K 2317/94**

(86) International application number:

PCT/EP2018/064630

(87) International publication number:

WO 2018/224441 (13.12.2018 Gazette 2018/50)(54) **ANTI-CD3 EPSILON ANTIBODIES**

ANTI-CD3 EPSILON-ANTIKÖRPER

ANTICORPS ANTI CD3 EPSILON

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

Designated Validation States:

KH MA MD TN(30) Priority: **05.06.2017 US 201762515293 P****27.11.2017 EP 17203832**

(43) Date of publication of application:

15.04.2020 Bulletin 2020/16

(60) Divisional application:

25159929.6(73) Proprietor: **Numab Therapeutics AG****8810 Horgen (CH)**

(72) Inventors:

- **GUNDE, Tea**
8005 Zurich (CH)
- **HESS, Christian**
8045 Zurich (CH)
- **MEYER, Sebastian**
5445 Eggenwil (CH)

• **SIMONIN, Alexandre****68128 Rosenau (FR)**• **BELTRAMETTI, Teddy****6467 Schattdorf (CH)**• **URECH, David****8645 Jona (CH)**(74) Representative: **Wallinger Ricker Schlotter
Tostmann****Patent- und Rechtsanwälte mbB****Zweibrückenstraße 5-7****80331 München (DE)**

(56) References cited:

WO-A1-2015/063339 WO-A1-2015/181098**WO-A1-2016/020444 WO-A1-2016/071355****WO-A1-2016/184570 WO-A1-2017/023761****WO-A2-2010/037835 WO-A2-2012/143524****WO-A2-2016/014974**• **ANDRES LOPEZ-ALBAITERO ET AL:**

**"Overcoming resistance to HER2-targeted
therapy with a novel HER2/CD3 bispecific
antibody", ONCOIMMUNOLOGY, vol. 6, no. 3, 4
March 2017 (2017-03-04), pages e1267891,
XP055374515, DOI: 10.1080/
2162402X.2016.1267891**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 634 998 B8

- BORTOLETTO NICOLA ET AL: "Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells", EUROPEAN JOURNAL OF IMMUNOLOGY,, vol. 32, no. 11, 1 November 2002 (2002-11-01), pages 3102 - 3107, XP002436763, ISSN: 0014-2980, DOI: 10.1002/1521-4141(200211)32:11<3102::AID-IMMU3102>3.0.CO;2-C